Volume 27 Issue 8, August 2021
Article | 24 June 2021
Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection
Multiyear analysis of antibody responses in recipients of the dengue vaccine Dengvaxia in the Philippines supports their utility as a predictor of protection against disease, and reveals that Dengvaxia efficacy declines 3 years after complete vaccination.
Henrik Salje, Maria Theresa Alera, Alan L. Rothman